Blood transfusions with high levels of contaminating soluble HLA-I correlate with levels of soluble CD8 in recipients' plasma; a new control factor in soluble HLA-I-mediated transfusion-modulated immunomodulation?

Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s105-8. doi: 10.2450/2012.0199-12. Epub 2012 Dec 21.

Abstract

Background: The cause of transfusion-related immunomodulation (TRIM) has proved tantalisingly elusive. An ever-growing body of evidence indicates that the infusion of large amounts of soluble and cell-associated antigens into a recipient can somehow induce TRIM. One soluble molecule that has been implicated in TRIM is soluble human leucocyte antigen I (sHLA-I). However, patients infused with large amounts of sHLA-I do not always and unambiguously experience TRIM. As soluble CD8 (sCD8) molecules have been shown to capable of binding membrane and soluble HLA-I molecules, we focused on sCD8 as a possible modulator of sHLA-I-mediated TRIM.

Material and methods: To this aim we compared the up-regulation of circulating sCD8 in plasma from patients suffering from the same pathology, but chronically transfused with two different blood derivatives: pre- and post-storage leucodepleted red blood cells which contain low and high levels of contaminating sHLA-I, respectively.

Results: Significantly larger amounts of sCD8 circulating molecules were detectable in the plasma of patients transfused with post-storage leucodepleted red blood cells whose supernatants contained significantly larger amounts of sHLA-I contaminating molecules.

Conclusion: With the limitation of indirect evidence, this report introduces a new facet of the bioactivity of sCD8 as a possible modulator of sHLA-I-mediated TRIM.

Publication types

  • Comparative Study

MeSH terms

  • Blood Preservation
  • CD8 Antigens / blood*
  • CD8 Antigens / physiology
  • CD8-Positive T-Lymphocytes / metabolism
  • Erythrocyte Transfusion / adverse effects*
  • Histocompatibility Antigens Class I / blood
  • Histocompatibility Antigens Class I / immunology*
  • Humans
  • Immunosuppression Therapy*
  • Leukocyte Reduction Procedures
  • Plasma
  • Solubility
  • beta-Thalassemia / blood
  • beta-Thalassemia / therapy

Substances

  • CD8 Antigens
  • Histocompatibility Antigens Class I